EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Calprotectin Is a Circulating Biomarker and Potential Therapeutic Target for Sarcopenia in Chronic Obstructive Pulmonary Disease

Liwei Liao, Jiaye Li, Weidong Xu, Yan Yin, Zilin Wang, Chang Li, Yanxia Li, Xiaoming Zhou, Mingming Deng, Gang Hou iD

Journal of Cachexia, Sarcopenia and Muscle · 2026

DOI: 10.1002/jcsm.70196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2026. Verfasst von Liwei Liao und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respir…. Hauptthemen laut MEDLINE: Sarcopenia, Pulmonary Disease, Chronic Obstructive, Biomarkers, Leukocyte L1 Antigen Complex. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Research and Development Program of Heilongjiang, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sarcopenia, an important complication of chronic obstructive pulmonary disease (COPD), is significantly associated with increased mortality. Systemic inflammation is an important trigger of COPD‐related skeletal muscle dysfunction. Calprotectin is a damage‐associated molecular pattern involved in the inflammatory response, but its exact role and mode of action in COPD‐related skeletal muscle dysfunction remain unclear. This study aimed to determine whether calprotectin is involved in COPD‐related sarcopenia.

Methods

In this study, 235 patients with stable COPD were divided into the development ( n = 117) and validation ( n = 118) groups, and serum calprotectin concentrations were measured by enzyme‐linked immunosorbent assays (ELISAs). Paquinimod, an oral calprotectin‐specific inhibitor, was used to investigate the involvement of calprotectin in cigarette smoke (CS)‐induced skeletal muscle dysfunction in vivo.

Results

Handgrip strength and quadriceps muscle strength, essential indicators of muscle strength, were negatively correlated with serum calprotectin levels ( r = −0.367, p < 0.001; r = −0.409, p < 0.001). The 5‐time sit‐to‐stand test results, which reflect endurance and physical strength, were positively correlated with serum calprotectin levels ( r = 0.290, p = 0.006). Ultrasound measurement of the rectus femoris muscle revealed negative correlations of serum calprotectin levels with both muscle thickness ( r = −0.448, p < 0.001) and cross‐sectional area ( r = −0.495, p < 0.001). Furthermore, serum calprotectin levels were significantly greater in patients with sarcopenia than in those without sarcopenia (90.09 ± 25.72 ng/mL vs. 59.56 ± 23.22 ng/mL, p < 0.001). Importantly, serum calprotectin levels could effectively predict sarcopenia in COPD patients in the development set (AUC = 0.811) and validation set (AUC = 0.805). In C57BL/6 mice with CS‐induced muscle dysfunction, paquinimod (10 mg/kg/day) reduced CS‐induced muscle mass loss (skeletal muscle weight 1.15% ± 0.09% vs. 1.33% ± 0.09%; p = 0.005) and increased the muscle cross‐sectional area (1375 ± 536.9 μm 2 vs. 2094 ± 470.2 μm 2 ; p < 0.001). Paquinimod also reduced CS‐induced muscle weakness, as indicated by increased grip strength (214.9 ± 31.38 g vs. 333.1 ± 34.93 g; p < 0.01). Paquinimod inhibited ubiquitin–proteasome system activity, reduced protein degradation marker levels, attenuated oxidative stress and increased antioxidant enzyme levels in CS‐exposed mice.

Conclusions

Serum calprotectin levels can be used to accurately predict sarcopenia in patients with COPD, and the calprotectin inhibitor paquinimod is a potential treatment for CS‐induced skeletal muscle dysfunction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcopeniaPulmonary Disease, Chronic ObstructiveBiomarkersLeukocyte L1 Antigen ComplexHumansMaleFemaleAgedAnimalsMiddle AgedMuscle, SkeletalMice

Stichwörter der Autor:innen

chronic obstructive pulmonary disease (COPD)paquinimodcalprotectinsarcopenia

Substanzen

BiomarkersLeukocyte L1 Antigen Complex

Autor:innen und Institutionen

  • National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of…
  • China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Department of Pulmonary and Critical Care Medicine, First Hospital of China Medical University, Shenyang, China.
  • Respiratory Department, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
  • Respiratory Department, Center for Pulmonary Vascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.

ORCID-Profile: Gang Hou

Förderung

  • National Natural Science Foundation of China
  • Key Research and Development Program of Heilongjiang
  • Fundamental Research Funds for the Central Universities
  • State Key Laboratory of Respiratory Health and Multimorbidity, state Key Laboratory Special Fund

Zitieren

APA

Liao, L., Li, J., Xu, W., Yin, Y., Wang, Z., Li, C., Li, Y., Zhou, X., Deng, M., & Hou, G. (2026). Calprotectin Is a Circulating Biomarker and Potential Therapeutic Target for Sarcopenia in Chronic Obstructive Pulmonary Disease. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.70196

Vancouver

Liao L, Li J, Xu W, Yin Y, Wang Z, Li C, et al. Calprotectin Is a Circulating Biomarker and Potential Therapeutic Target for Sarcopenia in Chronic Obstructive Pulmonary Disease. Journal of Cachexia, Sarcopenia and Muscle. 2026. doi:10.1002/jcsm.70196

BibTeX
@article{Liao2026,
  author = {Liao, Liwei and Li, Jiaye and Xu, Weidong and Yin, Yan and Wang, Zilin and Li, Chang and Li, Yanxia and Zhou, Xiaoming and Deng, Mingming and Hou, Gang},
  title = {Calprotectin Is a Circulating Biomarker and Potential Therapeutic Target for Sarcopenia in Chronic Obstructive Pulmonary Disease},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2026},
  doi = {10.1002/jcsm.70196}
}
Kostenlos starten →